JP2008524228A5 - - Google Patents

Download PDF

Info

Publication number
JP2008524228A5
JP2008524228A5 JP2007546841A JP2007546841A JP2008524228A5 JP 2008524228 A5 JP2008524228 A5 JP 2008524228A5 JP 2007546841 A JP2007546841 A JP 2007546841A JP 2007546841 A JP2007546841 A JP 2007546841A JP 2008524228 A5 JP2008524228 A5 JP 2008524228A5
Authority
JP
Japan
Prior art keywords
thrombosis
embolism
thromboembolic
disease
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007546841A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008524228A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/045158 external-priority patent/WO2006065853A2/en
Publication of JP2008524228A publication Critical patent/JP2008524228A/ja
Publication of JP2008524228A5 publication Critical patent/JP2008524228A5/ja
Pending legal-status Critical Current

Links

JP2007546841A 2004-12-15 2005-12-14 Xa因子阻害剤の結晶フォーム Pending JP2008524228A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63638704P 2004-12-15 2004-12-15
US73798505P 2005-11-18 2005-11-18
PCT/US2005/045158 WO2006065853A2 (en) 2004-12-15 2005-12-14 Crystalline forms of a factor xa inhibitor

Publications (2)

Publication Number Publication Date
JP2008524228A JP2008524228A (ja) 2008-07-10
JP2008524228A5 true JP2008524228A5 (enExample) 2009-02-05

Family

ID=36384503

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007546841A Pending JP2008524228A (ja) 2004-12-15 2005-12-14 Xa因子阻害剤の結晶フォーム

Country Status (15)

Country Link
US (2) US7371864B2 (enExample)
EP (1) EP1828187A2 (enExample)
JP (1) JP2008524228A (enExample)
KR (1) KR20070087606A (enExample)
AR (1) AR053990A1 (enExample)
AU (1) AU2005317158A1 (enExample)
BR (1) BRPI0519331A2 (enExample)
CA (1) CA2589886A1 (enExample)
IL (1) IL183825A0 (enExample)
MX (1) MX2007006919A (enExample)
NO (1) NO20072666L (enExample)
PE (1) PE20060739A1 (enExample)
RU (1) RU2007126770A (enExample)
TW (1) TW200634011A (enExample)
WO (1) WO2006065853A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2636757B1 (en) 2008-05-27 2016-11-23 Dako Denmark A/S Compositions and methods for detection of chromosomal aberrations with novel hybridization buffers
US9303287B2 (en) 2009-02-26 2016-04-05 Dako Denmark A/S Compositions and methods for RNA hybridization applications
WO2013046033A1 (en) 2011-09-30 2013-04-04 Dako Denmark A/S Hybridization compositions and methods using formamide
EP3252173A1 (en) 2011-10-21 2017-12-06 Dako Denmark A/S Hybridization compositions and methods
UY38438A (es) 2018-11-02 2020-05-29 Biocryst Pharm Inc Sales cristalinas de un inhibidor de calicreína plasmática

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI331526B (en) * 2001-09-21 2010-10-11 Bristol Myers Squibb Pharma Co Lactam-containing compounds and derivatives thereof as factor xa inhibitors
GEP20074098B (en) * 2001-09-21 2007-05-10 Bristol Myers Squibb Co Lactam-containing compounds and derivatives thereof as factor xa inhibitors
US20060069085A1 (en) * 2004-09-28 2006-03-30 Rulin Zhao Preparation of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones
US20060069260A1 (en) * 2004-09-28 2006-03-30 Huiping Zhang Preparation of N-aryl pyridones
US7388096B2 (en) 2004-09-28 2008-06-17 Bristol-Myers Squibb Company Crystalline forms of a factor Xa inhibitor
US7304157B2 (en) * 2004-09-28 2007-12-04 Bristol-Myers Squibb Company Efficient synthesis of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones

Similar Documents

Publication Publication Date Title
JP2012532112A5 (enExample)
JP2015533168A5 (enExample)
JP2014532070A5 (enExample)
JP2011520967A5 (enExample)
HRP20201927T1 (hr) PIRIMIDINONI KAO INHIBITORI FAKTORA XIa
JP2007511487A5 (enExample)
JP2014521700A5 (enExample)
JP2006525328A5 (enExample)
JP2014530240A5 (enExample)
JP2007533672A5 (enExample)
RU2007116150A (ru) Полиморфные формы 6-[2-(метилкарбамоил)фенилсульфанил]-3-е-[2-[пиридин-2-ил)этенил]индазола
FI3562487T3 (fi) Metalloentsyymi-inhibiittoriyhdisteitä
JP2025131625A5 (enExample)
JPH07506354A (ja) 抗虚血薬剤
JP2010516702A5 (enExample)
Kerin et al. Coronary artery spasm associated with variant angina pectoris
JP2018525371A5 (enExample)
WO1994012499A1 (fr) Derive de 1,8-naphthyridin-2-one et utilisation de ce derive
JP2005502579A5 (enExample)
JP2009543844A (ja) 直接トロンビン阻害剤の新しい小児適応症
JP2009521472A (ja) 心肺手術の合併症の予防としてのトロンビンレセプターアンタゴニスト
JP2008524228A5 (enExample)
JP2018522024A5 (enExample)
DK164638B (da) Kombinationspraeparat af pyrimido-pyrimidiner og acetylsalicylsyre og/eller deres farmaceutisk acceptable salte, fremgangsmaade til dets fremstilling samt anvendelse af pyrimido-pyrimidiner og acetylsalicylsyre og/eller salte deraf sammen med farmaceutiske baerere til fremstilling af et kombinationspraeparat
JP2007506679A5 (enExample)